General health of patients with diabetic macular edema-The LIPSIA study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 07 01 2021
accepted: 13 05 2021
entrez: 11 6 2021
pubmed: 12 6 2021
medline: 25 2 2023
Statut: epublish

Résumé

Cardiovascular risk factors such as hypertension or dyslipidemia can influence the incidence and progression of diabetic retinopathy (DR) and diabetic macular edema (DME). The aim of this study is to describe the comorbidities in patients with DME. Prospective, monocentric observational study. Patients presenting for the treatment of DME received laboratory and clinical examinations including 24-hour blood pressure measurement. Seventy-five consecutive patients were included in the study. The mean age was 61.0 ± 14.5 years, and 83% had type 2 diabetes. The mean body mass index (BMI) was 32.8 ± 6.0 kg/m2. Overweight (BMI ≥ 25 kg/m2) was present in 92% of all patients. HbA1c values were > 7.0% in 57%. Although 87% of the patients already received antihypertensive therapy, the blood pressure (BP) of 82% was still above the recommended target values of systolic < 140 mmHg and diastolic < 80 mmHg. An insufficient nocturnal fall of the systolic BP (< 10%, non-dipping or reverse dipping) was observed in 62%. In 83% of the patients the glomerular filtration rate was ≤ 90 ml/min/1.73m2. Despite 65% of the cohort already receiving lipid-lowering therapy, LDL cholesterol was above the target value of 1.4 mmol/l in 93%. All patients had at least one cardiovascular risk factor in addition to diabetes (overweight, hypertension, insufficient nocturnal BP fall, dyslipidemia, or renal dysfunction) and 86% had ≥ 3 risk factors. DME patients are characterized by highly prevalent cardiovascular risk factors that are poorly controlled. These comorbidities reduce the prognosis and negatively influence existing DR and DME. The data reveal an important opportunity for improving patient care by interaction of the ophthalmologist with the general practitioner and internal specialists for the detection and treatment of these conditions.

Identifiants

pubmed: 34115786
doi: 10.1371/journal.pone.0252321
pii: PONE-D-21-00608
pmc: PMC8195383
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0252321

Déclaration de conflit d'intérêts

The study was funded by a grant to MR by Novartis Pharma (Grant number: MRTH258A_FVMR002). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

JAMA Ophthalmol. 2016 Mar;134(3):251-7
pubmed: 26720805
Diabetes Care. 1998 Dec;21(12):2149-51
pubmed: 9839109
Cytokine. 2008 Jul;43(1):98-101
pubmed: 18455421
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127
pubmed: 25637717
JAMA Ophthalmol. 2018 Jan 1;136(1):68-74
pubmed: 29167896
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Curr Med Res Opin. 2016 Jul;32(7):1243-52
pubmed: 26986190
Ophthalmology. 1998 Oct;105(10):1801-15
pubmed: 9787347
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148
pubmed: 30043039
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2639-2653
pubmed: 31654188
Ann Intern Med. 2018 Apr 17;168(8):569-576
pubmed: 29507945
Cardiovasc Diabetol. 2017 Jan 7;16(1):4
pubmed: 28061854
Atheroscler Suppl. 2019 Dec;40:49-54
pubmed: 31818450
Ophthalmology. 2008 Nov;115(11):1859-68
pubmed: 19068374
J Diabetes Metab Disord. 2018 Apr 28;17(1):63-69
pubmed: 30288386
JAMA Ophthalmol. 2019 Apr 1;137(4):363-371
pubmed: 30629109
Arch Intern Med. 1997 Mar 24;157(6):650-6
pubmed: 9080919
Sci Rep. 2017 Jul 7;7(1):4867
pubmed: 28687808
Br J Ophthalmol. 2002 Apr;86(4):365-7
pubmed: 11914198
Eur J Ophthalmol. 1995 Apr-Jun;5(2):119-23
pubmed: 7549440
Diabetol Int. 2018 Apr 26;10(1):3-11
pubmed: 30800559
Atherosclerosis. 2004 Jun;174(2):225-33
pubmed: 15136052
Acta Ophthalmol. 2009 Aug;87(5):501-5
pubmed: 18700887
BMJ Open Diabetes Res Care. 2020 May;8(1):
pubmed: 32475840
JAMA Ophthalmol. 2015 May;133(5):503-10
pubmed: 25502808
Ophthalmology. 1991 May;98(5 Suppl):766-85
pubmed: 2062512
Eye (Lond). 2019 Jun;33(6):980-987
pubmed: 30760896
Clin Ter. 2013;164(2):e121-6
pubmed: 23698213
Atherosclerosis. 2019 Dec;291:62-70
pubmed: 31704552
Hypertension. 2016 Apr;67(4):693-700
pubmed: 26902495
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Ophthalmologica. 2017;237(4):185-222
pubmed: 28423385
Diabetes Care. 1993 May;16(5):755-8
pubmed: 8495616
Arch Ophthalmol. 2003 Feb;121(2):245-51
pubmed: 12583792
Obes Rev. 2017 Mar;18(3):309-316
pubmed: 28085992
JAMA. 2016 Apr 26;315(16):1778-9
pubmed: 27115379
Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S73-S92
pubmed: 31860927
Ophthalmology. 2009 Mar;116(3):497-503
pubmed: 19167079
Diabetes Care. 2020 Jun;43(6):1200-1208
pubmed: 32161049
Diabetes Care. 2016 May;39(5):677-85
pubmed: 26740635
J Hypertens. 2013 Sep;31(9):1731-68
pubmed: 24029863
Ophthalmology. 2006 Dec;113(12):2231-6
pubmed: 16996597

Auteurs

Catharina Busch (C)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Julius L Katzmann (JL)

Department of Cardiology, University Hospital Leipzig, Leipzig, Germany.

Claudia Jochmann (C)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Jan Darius Unterlauft (JD)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Daniela Vollhardt (D)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Peter Wiedemann (P)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Ulrich Laufs (U)

Department of Cardiology, University Hospital Leipzig, Leipzig, Germany.

Matus Rehak (M)

Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH